Compare · CNMD vs STXS
CNMD vs STXS
Side-by-side comparison of CONMED Corporation (CNMD) and Stereotaxis Inc. (STXS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNMD and STXS operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- CNMD is the larger of the two at $1.38B, about 13.6x STXS ($101.4M).
- STXS has been more active in the news (12 items in the past 4 weeks vs 6 for CNMD).
- CNMD has more recent analyst coverage (16 ratings vs 6 for STXS).
- Company
- CONMED Corporation
- Stereotaxis Inc.
- Price
- -
- -
- Market cap
- $1.38B
- $101.4M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- AMEX
- IPO
- 1987
- News (4w)
- 6
- 12
- Recent ratings
- 16
- 6
CONMED Corporation
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. It offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
Stereotaxis Inc.
Stereotaxis, Inc. designs, manufactures, and markets robotic magnetic navigation (RMN) systems for use in hospital's interventional surgical suite to improve the treatment of arrhythmias and coronary artery disease in the United States and internationally. Its RMN systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was founded in 1990 and is based in St. Louis, Missouri.
Latest CNMD
- Amendment: SEC Form SCHEDULE 13G/A filed by CONMED Corporation
- General Counsel & Corp Sec Foust Hollie K converted options into 4,000 shares and covered exercise/tax liability with 1,124 shares, increasing direct ownership by 100% to 5,762 units (SEC Form 4)
- CONMED Corporation to Participate in the Jefferies Global Healthcare Conference
- SEC Form 10-Q filed by CONMED Corporation
- SEC Form 8-K filed by CONMED Corporation
- CONMED Corporation Reports Third Quarter 2026 Financial Results; Updates Full Year 2026 Guidance
- CONMED Corporation to Report Third Quarter 2026 Financial Results on October 28, 2026
- Director Kelderman Kim converted options into 500 shares (SEC Form 4)
- CONMED Corporation to Participate in the Wells Fargo 21st Annual Healthcare Conference
- SEC Form 10-Q filed by CONMED Corporation
Latest STXS
- Director Arun Swarup Menawat bought $99,984 worth of shares (121,561 units at $0.82), increasing direct ownership by 12% to 1,157,121 units (SEC Form 4)
- Director David Benfer bought $24,870 worth of shares (30,000 units at $0.83) (SEC Form 4)
- Director Paul J Isaac bought $10,900 worth of shares (13,300 units at $0.82) (SEC Form 4)
- SEC Form 10-Q filed by Stereotaxis Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Stereotaxis Inc.
- Large owner Dafna Capital Management Llc acquired $4,000,000,000,000 worth of Convertible Promissory Notes (2,000,000 units at $2,000,000.00) (SEC Form 4)
- Director Fischel Nathan acquired $4,000,000,000,000 worth of Convertible Promissory Notes (2,000,000 units at $2,000,000.00) (SEC Form 4)
- Stereotaxis Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Stereotaxis Reports 2026 Third Quarter Financial Results & Business Updates
- Stereotaxis Announces Convertible Note Financing of Up To $24 Million